What question did this study set out to answer?

To evaluate the efficacy and tolerability of indinavir combined with zidovudine and lamivudine compared to two-drug and single-drug regimens in zidovudine-experienced adults with HIV.

September 11, 1997New England Journal of MedicineOpen Access

Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy

View Full Paper

Ask AI

Bookmark

To evaluate the efficacy and tolerability of indinavir combined with zidovudine and lamivudine compared to two-drug and single-drug regimens in zidovudine-experienced adults with HIV.
Double-blind randomized trial involving 97 HIV-infected adults with prior zidovudine therapy (≥6 months), CD4 counts of 50 to 400 cells/mm³, and baseline HIV RNA ≥20,000 copies/mL.
Participants were randomly assigned to indinavir monotherapy (800 mg every 8 hours), zidovudine (200 mg every 8 hours) plus lamivudine (150 mg twice daily), or all three drugs for up to 52 weeks.
HIV RNA decreased to <500 copies/mL at week 24 in 90% (28/31) of the three-drug group, 43% (12/28) of the indinavir group, and 0% (0/30) of the zidovudine-lamivudine group (P<0.001 for each comparison against triple therapy).
Increases in CD4 cell counts at 24 weeks were significantly higher in both indinavir-containing arms compared to the zidovudine-lamivudine arm (P≤0.01 for each comparison), with viral suppression and CD4 recovery persisting through 52 weeks.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized double-blind trial shows superior viral suppression in treatment-experienced HIV, indicating the sustained benefit of indinavir-based triple therapy.

Cite This Study

Gulick et al. (1997) studied this question.

synapsesocial.com/papers/6a13aebc496bd0bf6e39c9cc https://doi.org/10.1056/nejm199709113371102

View Full Paper

Ask AI

Bookmark

Implication

Randomized double-blind trial shows superior viral suppression in treatment-experienced HIV, indicating the sustained benefit of indinavir-based triple therapy.

Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy

Key Points

Discussion

Implication

Cite This Study

Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy

Key Points

Discussion

Implication

Cite This Study